OpenEvidence

AI clinical search engine.

Free planHealthcare

Visit openevidence.comCompare

+48.3%Search trend (3 mo) · DataForSEO

805,933Monthly searches

HealthcarePrimary category

N/ANo reviews yet

About OpenEvidence

Picture this: you're a hospitalist at 2 a.m., managing a complex oncology patient, and you need to cross-reference NCCN treatment algorithms against the latest Cochrane evidence without leaving the bedside workflow. That's the exact scenario OpenEvidence is built for. It's an AI copilot for physicians that pulls from signed content agreements with NEJM, JAMA, Nature, Cochrane, and NCCN. Meaning the answers it surfaces are grounded in full-text clinical findings, figures, tables, and treatment guidelines from the journals that actually move clinical practice.

The scale here is hard to ignore: OpenEvidence claims over 200 million AI-powered clinical consultations from U.S. doctors and other frontline clinicians, and says more than 100 million Americans will be treated this year by a clinician using the platform. It's positioned itself as the most widely used medical AI among verified U.S. clinicians. Not a general-purpose chatbot with a medical skin on top, but a purpose-built tool with formal partnerships that give it access to content most AI tools can't legally touch.

The team is almost aggressively academic. PhDs from MIT, Harvard, and Stanford, including researchers who worked directly with Jacob Andreas, Peter Szolovits, and Antonio Torralba. The founder, Daniel Nadler (PhD, Harvard), made both the TIME100 Most Influential People in AI and TIME100 Most Influential People in Health lists. OpenEvidence has also acquired at least two startups. Amaro and Vocode. Suggesting it's building out capabilities beyond just literature retrieval. If you're a clinician who wants AI assistance that's actually anchored to peer-reviewed evidence rather than a probabilistic guess, this is the most credible option currently operating at scale in the U.S.

Key features

Full-text access to top medical journals

OpenEvidence has signed content agreements with NEJM, JAMA and the JAMA Network specialty journals, Nature and the Nature Portfolio, Cochrane Systematic Reviews, and NCCN, giving it legal access to figures, tables, multimedia, and full-text clinical findings that general AI tools can't retrieve.

NCCN Guidelines Treatment Algorithms

Through its official AI collaboration with the National Comprehensive Cancer Network, OpenEvidence surfaces NCCN Guidelines Treatment Algorithms directly, which is critical for oncology decision support at the point of care.

Point-of-care AI consultation

The platform is designed as an AI copilot for high-stakes clinical decisions, not a research tool you use after the fact. It's built to fit into the moment a clinician needs an answer.

Verified clinician access

OpenEvidence restricts access to verified U.S. clinicians, which is part of why it can claim the most widely used medical AI distinction among that specific population rather than a general consumer base.

Acquired AI capabilities via Amaro and Vocode

OpenEvidence has absorbed at least two startups. Amaro and Vocode (a voice AI company). Indicating the platform is expanding beyond text-based retrieval into additional interaction modalities and clinical workflow integrations.

Best for

U.S.-based physicians needing point-of-care evidence retrieval
Oncologists referencing NCCN treatment algorithms in real time
Hospitalists and frontline clinicians managing complex, time-sensitive cases
Clinicians who want AI answers grounded in NEJM, JAMA, or Cochrane rather than general web data

Skip if

Skip this if you're outside the U.S.. Access is restricted to verified U.S. clinicians, so international practitioners won't qualify
Skip this if you're a patient or non-clinician researcher. This isn't a consumer health tool and verification requirements will block you
Skip this if you need transparent pricing before committing. There's no public pricing page, so cost is unknown until you're inside the signup flow

Pros & cons

Pros

Formal content agreements with NEJM, JAMA, Nature, Cochrane, and NCCN give it access to full-text clinical content that competitors can't legally use
200 million AI-powered clinical consultations is a real usage signal, not a vanity metric. It suggests the product has genuine clinical adoption
The team has unusually deep research credentials, with multiple MIT and Harvard PhDs who worked directly with leading NLP researchers
NCCN Guidelines Treatment Algorithms integration is a specific, high-value feature for oncology that's hard to replicate without a formal partnership

Cons

No public pricing. You can't evaluate cost without going through the signup process, which is a friction point for anyone doing vendor comparisons
Access is limited to verified U.S. clinicians, so it's entirely unavailable to international doctors, researchers, or allied health professionals
The platform's capabilities beyond journal retrieval and NCCN algorithms are unclear from public-facing information. Most details only surface after signup
No mention of EHR integration, which is a significant gap if the goal is true point-of-care workflow embedding rather than a parallel lookup tool

Frequently asked questions

Is OpenEvidence only for doctors?

Yes. Access is restricted to verified U.S. clinicians, so it's not available to patients, students, or non-clinical researchers. The verification requirement is part of what enables its content partnerships with NEJM and JAMA.

What journals does OpenEvidence actually have access to?

OpenEvidence has signed content agreements with at least 5 major publishers: NEJM, JAMA and the JAMA Network specialty journals, Nature and the Nature Portfolio, Cochrane Systematic Reviews, and NCCN. Access includes full-text articles, figures, tables, and multimedia, not just abstracts.

How widely used is OpenEvidence among U.S. clinicians?

The company claims over 200 million AI-powered clinical consultations to date and projects that more than 100 million Americans will be treated this year by a clinician using the platform. It describes itself as the most widely used medical AI among verified U.S. clinicians.

How does OpenEvidence compare to just using ChatGPT for clinical questions?

ChatGPT doesn't have legal access to full-text NEJM or JAMA articles and isn't restricted to verified clinicians, which means it can't surface the same sourced, guideline-level content. OpenEvidence's NCCN Guidelines Treatment Algorithms integration alone is something ChatGPT can't replicate.

Who founded OpenEvidence and what's their background?

The company was founded by Daniel Nadler, who holds a PhD from Harvard and was named to both the TIME100 Most Influential People in AI and TIME100 Most Influential People in Health lists. The broader team includes PhDs from MIT, Harvard, and Stanford, several of whom previously worked at NEJM Group, Google, and Palantir.

How OpenEvidence compares

OpenEvidence vs ChatGPT

ChatGPT has no formal agreements with NEJM, JAMA, or NCCN, so it can't surface full-text clinical findings or treatment algorithms. It's a general reasoner, not a verified clinical evidence tool.

OpenEvidence vs UpToDate

UpToDate is the incumbent clinical reference tool with broad hospital adoption, but it's a curated editorial product rather than an AI that synthesizes across live journal content from Cochrane, Nature, and NCCN simultaneously.

OpenEvidence vs Perplexity

Perplexity can cite sources and search the web in real time, but it has no signed agreements with major medical publishers and isn't restricted to verified clinicians, making it unsuitable for high-stakes point-of-care decisions.

Reviews

No reviews yet, be the first.

More like OpenEvidenceAll healthcare tools

Own this tool?Claim the listing to get a verified badge and edit the details.